Global eosinophilic esophagitis treatment market was valued at $249.0 million in 2025 and is expected to reach $466.0 million by 2035, expanding at a CAGR of 6.5% over the forecast period from 2026 to 2035. The increasing prevalence of eosinophilic esophagitis (EoE) is a major driver supporting the growth of this market. Government health agencies, including the US Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), indicate that EoE is recognized as one of the most common causes of chronic esophageal inflammation and food impaction, particularly among children and young adults. According to epidemiological studies, in March 2025, EoE affects roughly 1 in 1,500 to 2,000 individuals in the US, with prevalence steadily rising over the past decade due to improved diagnostic awareness and expanded use of upper endoscopy and biopsy.
Browse the full report description of “Global Eosinophilic Esophagitis Treatment Market Size, Share & Trends Analysis Report By Product (Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, and Others), By Diagnosis (Upper Endoscopy, Esophagus Biopsy, and Blood Tests), and By Treatment (Dietary Therapy, Medication, and Dilation) Forecast, (2026-2035)” at https://www.omrglobal.com/industry-reports/eosinophilic-esophagitis-treatment-market
The condition is strongly associated with allergic disorders such as asthma, atopic dermatitis, and food allergies, all of which are also increasing globally according to government surveillance data. Earlier underdiagnosis has given way to more frequent and accurate identification, leading to a growing diagnosed patient pool requiring long-term management. Since EoE is a chronic, relapsing disease with no definitive cure, most patients require sustained dietary intervention, pharmacologic therapy, or both. This long-term treatment paradigm directly drives demand for corticosteroids, biologics, and supportive diagnostic procedures. As awareness expands among clinicians and patients, treatment initiation rates continue to rise, supporting consistent market expansion across hospital and specialty care settings.
Key Companies Driving Innovation in the Eosinophilic Esophagitis Treatment Market
The key players in the eosinophilic esophagitis treatment market include Sanofi SA, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca PLC, GlaxoSmithKline PLC, among others. These companies are advancing innovation in the eosinophilic esophagitis treatment market through the development of targeted biologic therapies, improved topical corticosteroid formulations, and novel dietary and drug-based approaches aimed at reducing esophageal inflammation and disease recurrence. Ongoing progress in precision medicine, better disease monitoring, and integration of real-world clinical data is helping address unmet needs in long-term disease control, symptom relief, and patient quality of life across global healthcare markets.
Market Coverage
Key questions addressed by the report.
Global Eosinophilic Esophagitis Treatment Market Report Segment
By Product
By Diagnosis
By Treatment
Global Eosinophilic Esophagitis Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/eosinophilic-esophagitis-treatment-market